vida: extract claims from 2026-04-08-steer-score-glp1-realworld-cv

- Source: inbox/queue/2026-04-08-steer-score-glp1-realworld-cv.md
- Domain: health
- Claims: 2, Entities: 0
- Enrichments: 1
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/obbba-snap-cuts-largest-food-assistance-reduction-history-186b-through-2034.md

@@ -0,0 +1,17 @@
+---
+type: claim
+domain: health
+description: The simultaneous removal of SNAP and Medicaid coverage reverses two parallel continuous-support interventions at the same time that evidence documents why continuous support is required for health outcomes
+confidence: experimental
+source: FRAC, Penn LDI, Urban Institute, Pew Charitable Trusts; CBO-scored $186B figure
+created: 2026-04-08
+title: OBBBA SNAP cuts represent the largest food assistance reduction in US history at $186 billion through 2034, removing continuous nutritional support from 2.4 million people despite evidence that SNAP participation reduces healthcare costs by 25 percent
+agent: vida
+scope: structural
+sourcer: FRAC / Penn LDI / Urban Institute / Pew Charitable Trusts
+related_claims: ["[[SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action]]", "[[value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk]]", "[[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]]"]
+---
+
+# OBBBA SNAP cuts represent the largest food assistance reduction in US history at $186 billion through 2034, removing continuous nutritional support from 2.4 million people despite evidence that SNAP participation reduces healthcare costs by 25 percent
+
+OBBBA's SNAP provisions cut $186 billion through 2034 through Thrifty Food Plan formula adjustments and work requirement expansions, making this the largest food assistance reduction in US history. The cuts are projected to remove 2.4 million people from SNAP by 2034, with more than 1 million older adults ages 55-64 at risk from work requirements alone, and 1 million+ facing short-term benefit loss in 2026. Implementation began December 1, 2025 in some states. The health implications are documented: SNAP participation is associated with 25% reduction in annual healthcare costs, and food insecurity is linked to higher risks of heart disease and diabetes. Among older adults specifically, food insecurity produces poorer diet quality, declining physical health, cognitive impairment risk, and harder chronic disease management. The OBBBA cuts are removing SNAP at the same time as Medicaid GLP-1 coverage is being cut, creating a double removal of continuous-support mechanisms. The Penn LDI projection of 93,000 deaths through 2039 from Medicaid cuts (3.2 million losing coverage) represents one mortality burden; the SNAP cuts are an additive burden affecting a partially overlapping population. The system is removing two parallel continuous-treatment interventions simultaneously, despite evidence that gains revert when support is removed.

domains/health/real-world-semaglutide-shows-stronger-mace-reduction-than-select-trial.md

@@ -0,0 +1,17 @@
+---
+type: claim
+domain: health
+description: SCORE study HR 0.43 for rMACE-3 vs SELECT trial HR ~0.80, reflecting real-world treatment selection effects rather than superior efficacy
+confidence: experimental
+source: SCORE study (Smolderen et al. 2025), 9,321 semaglutide users matched to 18,642 controls
+created: 2026-04-08
+title: "Real-world semaglutide use in ASCVD patients shows 43-57% MACE reduction compared to 20% in SELECT trial because treated populations have better adherence and access creating positive selection bias"
+agent: vida
+scope: correlational
+sourcer: Smolderen et al.
+related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]"]
+---
+
+# Real-world semaglutide use in ASCVD patients shows 43-57% MACE reduction compared to 20% in SELECT trial because treated populations have better adherence and access creating positive selection bias
+
+The SCORE study tracked 9,321 individuals with ASCVD and overweight/obesity (without diabetes) who initiated semaglutide 2.4mg, matched to 18,642 controls over mean 200-day follow-up. Semaglutide was associated with HR 0.43 for revised 3-point MACE and HR 0.55 for revised 5-point MACE (both p<0.001), alongside reductions in all-cause mortality, cardiovascular mortality, and heart failure hospitalization. These effect sizes are substantially larger than the SELECT trial's ~20% MACE reduction (HR ~0.80). The difference likely reflects positive selection bias: real-world treated patients have better healthcare access, higher adherence, more resources, and may be healthier at baseline despite matching attempts. This is not evidence that semaglutide works better in practice than in trials—it's evidence that the patients who get treated in practice are systematically different. However, the consistency of direction (benefit across all cardiovascular endpoints) in a real-world setting confirms that SELECT trial findings translate outside controlled trial populations. The study is Novo Nordisk-funded, adding another layer of interpretation caution.

domains/health/semaglutide-outperforms-tirzepatide-cardiovascular-outcomes-despite-inferior-weight-loss.md

@@ -0,0 +1,17 @@
+---
+type: claim
+domain: health
+description: "STEER study shows semaglutide reduces MACE by 22-29% vs tirzepatide in ASCVD patients, challenging the assumption that greater weight loss produces proportionally greater CV benefit"
+confidence: experimental
+source: STEER investigators 2026, 10,625 matched patients with ASCVD
+created: 2026-04-08
+title: Semaglutide produces superior cardiovascular outcomes compared to tirzepatide despite achieving less weight loss because GLP-1 receptor-specific cardiac mechanisms operate independently of weight reduction
+agent: vida
+scope: causal
+sourcer: STEER investigators
+related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]"]
+---
+
+# Semaglutide produces superior cardiovascular outcomes compared to tirzepatide despite achieving less weight loss because GLP-1 receptor-specific cardiac mechanisms operate independently of weight reduction
+
+The STEER study compared semaglutide to tirzepatide in 10,625 matched patients with overweight/obesity and established ASCVD without diabetes. Semaglutide demonstrated 29% lower risk of revised 3-point MACE and 22% lower risk of revised 5-point MACE compared to tirzepatide, with per-protocol analysis showing even stronger effects (43% and 57% reductions). This finding is counterintuitive because tirzepatide consistently achieves greater weight loss than semaglutide across trials. The divergence suggests that GLP-1 receptor activation produces cardiovascular benefits through mechanisms beyond weight reduction alone. GLP-1 receptors are directly expressed in cardiac tissue, while tirzepatide's dual GIP/GLP-1 receptor agonism may produce different cardiac effects. This challenges the prevailing model that weight loss is the primary mediator of GLP-1 cardiovascular benefit and suggests receptor-specific cardiac mechanisms matter independently. The finding is limited to established ASCVD patients (highest-risk subgroup) and requires replication, but represents a genuine mechanistic surprise.

domains/health/state-snap-cost-shifting-creates-fiscal-cascade-forcing-additional-benefit-cuts.md

@@ -0,0 +1,17 @@
+---
+type: claim
+domain: health
+description: "The mechanism is bidirectional fiscal pressure: states that implement federal SNAP work requirements take on new administrative costs, which may force state-level reductions in other health programs, creating a multiplier effect beyond the direct federal cuts"
+confidence: experimental
+source: Pew Charitable Trusts analysis of state cost projections
+created: 2026-04-08
+title: OBBBA SNAP cost-shifting to states creates a fiscal cascade where compliance with federal work requirements imposes $15 billion annual state costs, forcing states to cut additional health benefits to absorb the new burden
+agent: vida
+scope: structural
+sourcer: Pew Charitable Trusts
+related_claims: ["[[value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk]]"]
+---
+
+# OBBBA SNAP cost-shifting to states creates a fiscal cascade where compliance with federal work requirements imposes $15 billion annual state costs, forcing states to cut additional health benefits to absorb the new burden
+
+OBBBA shifts SNAP costs to states, with Pew analysis projecting states' collective SNAP costs will rise $15 billion annually once phased in. This creates a fiscal cascade mechanism: states facing dual cost pressure from new SNAP state share requirements and new Medicaid administrative requirements (all states must implement Medicaid work requirements by December 31, 2026) may be forced to cut additional benefits to absorb the federal cost shift. The mechanism is not just direct federal cuts—it's a structural transfer of fiscal burden that forces state-level trade-offs. States must choose between absorbing $15B in new costs, raising taxes, or cutting other programs. The Pew analysis explicitly notes states may be forced to cut additional benefits as the federal shift increases state costs. This is a multiplier effect: the $186B federal SNAP cut triggers state-level cuts in other health programs as states reallocate budgets to cover the new SNAP burden. The cascade is already materializing—7 states have pending Medicaid work requirement waivers (Arizona, Arkansas, Iowa, Montana, Ohio, South Carolina, Utah) and Nebraska is pursuing a state plan amendment, indicating states are actively restructuring programs to comply with federal requirements while managing new cost burdens.

inbox/archive/health/2026-04-08-steer-score-glp1-realworld-cv.md

@@ -7,9 +7,12 @@ date: 2026-01-01
 domain: health
 secondary_domains: []
 format: journal-article
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-04-08
 priority: high
 tags: [GLP-1, semaglutide, tirzepatide, cardiovascular, MACE, real-world-evidence, ASCVD, heart-failure]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content